Physician profile
David Bryant
NPI 1255382701
$3,308.91
in general payments reported to CMS, 2019-2025
20 companies · $814 in 2025
The $814 reported for 2025 was more than what 86% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $325 · 2020: $81.36 · 2021: $466 · 2022: $547 · 2023: $385 · 2024: $690 · 2025: $814.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,817 · Education: $72.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,816.99 |
| Education | $72.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,121.30 | 2019-2024 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $708.74 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| Abbvie INC. | $300.42 | 2020-2025 | |
| Amgen INC. | $179.08 | 2021-2025 | Otezla, Otezla, Enbrel |
| Leo Pharma INC. | $173.63 | 2021-2025 | Adbry, Anzupgo |
| Incyte Corporation | $140.18 | 2022-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $120.93 | 2019-2024 | Dupixent, Libtayo |
| Genzyme Corporation | $91.23 | 2025 | |
| Pfizer INC. | $86.76 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.37 | 2022-2025 | Spevigo |
| Galderma Laboratories, L.P. | $62.33 | 2024-2025 | Nemluvio |
| Celgene Corporation | $43.99 | 2019 | |
| Organon LLC | $43.55 | 2024-2025 | Vtama |
| Lilly USA, LLC | $41.01 | 2024-2025 | Taltz, Ebglyss |
| Journey Medical Corporation | $32.11 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $23.57 | 2025 | Sotyktu |
| Janssen Pharmaceuticals, INC | $23.12 | 2024 | Invega Sustenna, Invega Trinza |
| Sun Pharmaceutical Industries INC. | $22.73 | 2021 | |
| Almirall LLC | $19.74 | 2021 | |
| Stemline Therapeutics INC. | $12.12 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Bryant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.